Sensei and Instil Bio let go large chunks of workforces, shift pipelines

Clinical trial disappointments have led Sensei Biotherapeutics and Instil Bio to lay off 40% and 60% of employees, respectively.

A trial flop on its lead program, pushback from a German billionaire stockholder and a massive stock slide precede the pipeline makeover at Sensei. The biotech had 44 full-time workers as…